Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
ByHeart has expanded its voluntary recall to include all Whole Nutrition Infant Formula cans and Anywhere Pack products amid an investigation by the Food and…
Headline
A study published today by Nature found that as many as 5,000 steps per day can slow cognitive decline for individuals with early signs of Alzheimer’s disease…
Headline
Rural hospital leaders recently shared strategies and insights on improving safety culture, governance and care reliability at the AHA’s Rural Patient Safety…
Headline
The Food and Drug Administration sent a warning letter to Philips last month due to quality violations found at three of its medical device facilities earlier…
Blog
Public
Cross-industry insights and new technology are helping HCA Healthcare reduce risk, improve outcomes and lead the future of high-reliability careFor Randy Fagin…
Headline
The Food and Drug Administration has identified a Class I recall of Abiomed Automated Impella Controllers due to the potential for serious injury or death. The…